Adenoma Clinical Trial - Proton Therapy Research Infrastructure- ProTRAIT-

Status Recruiting

Clinical Trial Summary

The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D image and 3D dose information has been developed and deployed for proton therapy in the Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch proton and a representative group of photon therapy patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04648462
Study type	Observational [Patient Registry]
Source	Maastricht Radiation Oncology
Contact	Danielle Eekers
Phone	+31884455600
Email	danielle.eekers@maastro.nl
Status	Recruiting
Phase
Start date	January 1, 2018
Completion date	January 1, 2035

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05551052` - CRC Detection Reliable Assessment With Blood
Recruiting	`NCT02545699` - Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy	N/A
Completed	`NCT01802008` - Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times	N/A
Recruiting	`NCT01211132` - Cap Assisted Colonoscopy for the Detection of Colon Polyps	N/A
Completed	`NCT04287335` - Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China
Not yet recruiting	`NCT06398418` - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors	Phase 1
Recruiting	`NCT05362344` - Colorectal Cancer Screening in Cystic Fibrosis
Completed	`NCT03268200` - The Effect of Segmental Re-examination of Colon for Adenoma Detection in Colonoscopy	N/A
Recruiting	`NCT04591145` - Multi-center Validation of a Deep Learning Based Bowel Preparation Evaluation System
Completed	`NCT02978664` - The Impact of Distraction on Adenoma Detection Rate	N/A
Completed	`NCT00018551` - Chemoprevention With Folic Acid	Phase 2
Recruiting	`NCT05594576` - Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy	N/A
Not yet recruiting	`NCT04135716` - A Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy	N/A
Recruiting	`NCT02552017` - Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities	N/A
Recruiting	`NCT02288962` - Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas	Phase 3
Completed	`NCT02066064` - G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist	N/A
Completed	`NCT01749722` - Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy	N/A
Withdrawn	`NCT01546259` - Water Method in Low-body Mass Index (BMI) Female Patients With Unsedated Colonoscopy	N/A
Withdrawn	`NCT01546220` - Water Method in Elder Patients With Unsedated Colonoscopy	N/A
Withdrawn	`NCT01546246` - Water Method in Patients With Incomplete Colonoscopy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms